• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Wellspect HealthCare Launches Surity™ Female External Catheter Improving Care for Women Living with Severe Urinary Incontinence

    1/26/26 8:15:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care
    Get the next $XRAY alert in real time by email

    MÖLNDAL, Sweden, Jan. 26, 2026 /PRNewswire/ -- Wellspect HealthCare, a global provider of continence care solutions, today announced the U.S. launch of the innovative Surity™ Female External Catheter, a new non-invasive solution designed to support women living with severe urinary incontinence. Wellspect HealthCare has been a trusted healthcare leader and at the forefront of innovation for more than 40 years, with established product brands including LoFric® and Navina™. Surity™ marks Wellspect's entry into a new category, bringing people suffering from severe urinary incontinence, and their caregivers, a reliable and comfortable urinary incontinence management solution.

    Surity FEC on nightstand.

    Severe urinary incontinence is a defining challenge for more than 13 million Americansi and their caregivers. Despite disruptions to sleep, falls, dehydration, skin breakdown, emotional distress and caregiver exhaustion,ii,iii,iv,v,vi,vii there remain limited options for severe urinary incontinence management.viii Whether providing care at home or in a healthcare setting, women, their caregivers and clinicians want to feel capable and have reliable tools that reduce strain, simplify routines, and support dignified care. Designed to be non-invasive, easy to place, and suitable for use with compatible urine collection systems, Surity™ brings relevant comfort to an area of care where few options exist.

    "Severe urinary incontinence affects millions of women, many of whom live with multiple health conditions. The impact of severe urinary incontinence reaches far beyond the inconvenience of leaks, contributing to sleep loss, emotional distress and exhaustion for both patients and their caregivers," said Chris Schlenk, Group Vice President, Wellspect HealthCare. "As leaders in continence care, we're determined to support patients and caregivers by offering a reliable and accessible management option designed to restore comfort, rest and confidence to those who have lived with these silent struggles for too long."

    Engineered to prevent leakage, protect skin, and support extended overnight use, Surity™ helps women and their caregivers confidently manage incontinence care through seamless integration into daily routines. The device is intended to make management of severe urinary incontinence more predictable, addressing a significant gap in continence care across aging, neurologic, and mobility-limited populations.

    Wellspect will launch the advanced Surity™ Urinary Management System and male external catheter later this year. Surity™ Female External Catheter is now available for home purchase at www.surity.care and will soon be available to healthcare institutions.

    To learn more about Surity™ please visit www.surity.care.

    Pictures are available for download here

    For more details, please contact:

    Marion Par-Weixlberger | Vice President Public Relations, Corporate Communications & Brand

    [email protected]

    About Wellspect HealthCare

    Wellspect HealthCare, a subsidiary of Dentsply Sirona, is a leading global provider of innovative medical devices dedicated to improving the quality of life for individuals with bladder and bowel dysfunction.

    With approximately 1,200 employees worldwide, Wellspect is committed to making a real difference for people managing continence care needs, empowering them to live each day to the fullest.

    Wellspect delivers solutions that support safe bladder and bowel management, and continuously enhances the user experience, clinical performance, and service quality for healthcare professionals and users alike.

    As one of the world's leading manufacturers of intermittent urinary catheters, Wellspect has been at the forefront of innovation since 1983 with its LoFric® brand, which introduced the first hydrophilic-coated catheter.

    Wellspect has also pioneered the development of Navina™, an innovative transanal irrigation system designed to support individuals living with chronic bowel disorders.

    Every day, Wellspect strives to maintain the highest quality standards while minimizing the environmental impact of its products.

    Headquartered in Mölndal, Sweden, Wellspect operates in more than 40 countries, offering life-enhancing solutions to people around the world. Dentsply Sirona, the world's largest diversified manufacturer of professional dental products and technologies, is listed on Nasdaq under the symbol XRAY.

    LinkedIn: Wellspect HealthCare

    Facebook: Wellspect

    Instagram: Wellspect

    iLeslie SW, Tran LN, Puckett Y. Urinary Incontinence. [Updated 2024 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559095/

    iiDuncan I, Stocking A, Fitzner K, Ahmed T, Huynh N. The Prevalence of Incontinence and Its Association With Urinary Tract Infections, Dermatitis, Slips and Falls, and Behavioral Disturbances Among Older Adults in Medicare Fee-for-Service. J Wound Ostomy Continence Nurs. 2024 Mar-Apr 01;51(2):138-145. doi: 10.1097/WON.0000000000001054. PMID: 38527324; PMCID: PMC11008436.

    iiiAppeadu MK, Bordoni B. Falls and Fall Prevention in Older Adults. [Updated 2023 Jun 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560761/

    ivMayo Clinic Staff. "Bladder Control: Lifestyle Strategies Ease Problems." Mayo Clinic, May 10, 2025. https://www.mayoclinic.org/diseases-conditions/urinary-incontinence/in-depth/bladder-control-problem/art-20046597

    vNational Association for Continence. "The True Impact of Incontinence." NAFC (National Association for Continence), 2025. https://nafc.org/bhealth-blog/the-true-impact-of-incontinence/

    viCheng S, Lin D, Hu T, et al. Association of urinary incontinence and depression or anxiety: a meta-analysis. Journal of International Medical Research. 2020;48(6). doi:10.1177/0300060520931348

    viiFamily Caregiver Alliance. "Caring for Someone with Incontinence: Emotional and Social Issues." Family Caregiver Alliance, 2014. https://www.caregiver.org/resource/caring-someone-incontinence-emotional-and-social-issues/

    viiiBeeson T, Pittman J, Davis CR. Effectiveness of an External Urinary Device for Female Anatomy and Trends in Catheter-Associated Urinary Tract Infections. J Wound Ostomy Continence Nurs. 2023 Mar-Apr 01;50(2):137-141. doi: 10.1097/WON.0000000000000951. PMID: 36867037; PMCID: PMC9990593.

    Wellspect HealthCare logo

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/wellspect-healthcare-launches-surity-female-external-catheter-improving-care-for-women-living-with-severe-urinary-incontinence-302669931.html

    SOURCE Wellspect HealthCare

    Get the next $XRAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XRAY

    DatePrice TargetRatingAnalyst
    2/19/2026$17.00Neutral → Buy
    BofA Securities
    12/9/2025$12.00Underweight
    Barclays
    11/7/2025Outperform → Mkt Perform
    William Blair
    4/15/2025$14.00Overweight → Equal-Weight
    Morgan Stanley
    3/13/2025Buy → Hold
    Needham
    2/14/2025$20.00Equal Weight
    Wells Fargo
    1/23/2025$30.00 → $20.00Buy → Hold
    Jefferies
    1/7/2025$20.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $XRAY
    SEC Filings

    View All

    SEC Form 10-K filed by DENTSPLY SIRONA Inc.

    10-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    2/26/26 4:54:01 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    DENTSPLY SIRONA Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    2/26/26 4:13:30 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    DENTSPLY SIRONA Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    2/24/26 4:35:21 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucier Gregory T bought $186,675 worth of shares (15,000 units at $12.45) (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/9/26 4:20:49 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Forbes James D bought $62,400 worth of shares (5,000 units at $12.48), increasing direct ownership by 100% to 10,000 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/9/26 4:19:42 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Lucier Gregory T bought $707,379 worth of shares (50,000 units at $14.15) (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/3/26 7:12:19 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics

    Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United States. This milestone follows the completion of a clinical trial2 validating the system's significant potential across multiple dental specialties. The trial highlighted this first-of-its-kind technology's applicability in endodontics, periodontics, TMJ, tooth extraction, and orthodontics, offering non-ionizing imaging capabilities that can enhance diagnosis and treatment planning. CHARLOTTE, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona and Siemens Healthineers are pleased to sha

    3/9/26 8:30:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona to Participate in the Leerink Partners Global Healthcare Conference 2026

    CHARLOTTE, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will participate in the Leerink Partners Global Healthcare Conference. Management is scheduled to present on Tuesday, March 10, 2026, at 10:00 a.m. EST. Investors and other interested parties will be able to access a live audio webcast and an audio webcast replay by visiting the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation

    3/3/26 4:15:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook

    News Summary Q4 2025 net sales of $961 million increased 6.2%, constant currency sales increased 2.5%Q4 2025 reported net loss of ($146) million and diluted loss per share of ($0.74) driven by goodwill and intangible impairments of ($144) million, net of taxQ4 2025 adjusted EPS of $0.27FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50(1)Announced a restructuring initiative to redirect approximately $120 million annually into the Return-to-Growth Action Plan, prioritizing investments in accelerated innovation, clinical education, and sales team education focused on connected dentistryInitiated new capital allocation strategy by eliminating the dividend

    2/26/26 4:01:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President, CEO & Member of BOD Scavilla Daniel T

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/12/26 5:44:35 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by EVP, Chief Commercial Officer Denti Aldo Mariano Roberto

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/12/26 5:41:09 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by VP, Chief Accounting Officer Czerney Kevin

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/12/26 5:38:47 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dentsply Sirona upgraded by BofA Securities with a new price target

    BofA Securities upgraded Dentsply Sirona from Neutral to Buy and set a new price target of $17.00

    2/19/26 7:47:02 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Dentsply Sirona with a new price target

    Barclays initiated coverage of Dentsply Sirona with a rating of Underweight and set a new price target of $12.00

    12/9/25 8:44:01 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona downgraded by William Blair

    William Blair downgraded Dentsply Sirona from Outperform to Mkt Perform

    11/7/25 8:28:06 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Leadership Updates

    Live Leadership Updates

    View All

    Dentsply Sirona Appoints James Forbes and Brian McKeon to Board of Directors

    CHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) --  DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointments of James (Jim) D. Forbes and Brian P. McKeon to its Board of Directors (the "Board"), effective February 27, 2026. Mr. Forbes is a veteran healthcare investment banker with 30 years of experience helping companies develop strategies to drive profitable growth and long-term value creation. Mr. Forbes is widely recognized for advising healthcare companies on complex strategic transactions and capital markets engagements. He most recently served as Vice Chairman of Investment Banking at Morgan Stanley, and he previously held senior execu

    2/24/26 4:30:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Appoints Donald Zurbay to Board of Directors

    CHARLOTTE, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointment of Donald (Don) Zurbay to its Board of Directors (the "Board"), effective January 10, 2026. He will be joining the Board's Audit and Finance Committee. Mr. Zurbay brings extensive leadership experience in the dental and healthcare industries, and value creation across complex, global organizations. He most recently served as President and Chief Executive Officer (CEO) of Patterson Companies, following his tenure as Chief Financial Officer (CFO) from 2018 to 2022. During his tenure, Patterson maintained a longstanding dealer partnership

    1/13/26 8:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Appoints Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization

    CHARLOTTE, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the appointment of Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization, effective January 28. The appointment supports Dentsply Sirona's continued focus on strengthening commercial execution, deepening customer relationships and accelerating growth across the Americas. Mr. Bezjak is a seasoned commercial executive with more than 20 years of experience leading large-scale, multi-billion-dollar organizations in the medical device

    1/12/26 9:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Financials

    Live finance-specific insights

    View All

    Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook

    News Summary Q4 2025 net sales of $961 million increased 6.2%, constant currency sales increased 2.5%Q4 2025 reported net loss of ($146) million and diluted loss per share of ($0.74) driven by goodwill and intangible impairments of ($144) million, net of taxQ4 2025 adjusted EPS of $0.27FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50(1)Announced a restructuring initiative to redirect approximately $120 million annually into the Return-to-Growth Action Plan, prioritizing investments in accelerated innovation, clinical education, and sales team education focused on connected dentistryInitiated new capital allocation strategy by eliminating the dividend

    2/26/26 4:01:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona to Host Fourth Quarter and Full Year Conference Call on February 26

    CHARLOTTE, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, February 26, 2026, at 4:30 p.m. EST to review its fourth quarter and full year 2025 financial results. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Information The live webcast will be available on the Investors section of the Company's website at http

    2/5/26 4:15:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Declares Quarterly Cash Dividend

    CHARLOTTE, N.C., Dec. 15, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on January 9, 2026, to holders of record as of December 26, 2025. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including den

    12/15/25 8:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.

    SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    12/6/24 10:11:29 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

    SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    11/14/24 1:22:35 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

    SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    11/12/24 4:23:31 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care